[ad_1] Parexel Biotech, a division of drug development services company Parexel, has entered into a strategic partnership with Synairgen, a respiratory treatment development company. The two will collaborate in the conduct of a Phase III study on SNG001, in the inhaled formulation of a treatment with interferon beta (IFN-beta) for …
Read More »Synairgen joins Parexel Biotech to study the COVID-19 drug
